WeissLaw LLP Investigates BioClinica, Inc. Acquisition
WeissLaw LLP, a national class action and shareholder rights law firm
with offices in New York City and Los Angeles, is investigating possible
breaches of fiduciary duty and other violations of law by the Board of
Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ:
BIOC) arising from its agreement for BioClinica to be acquired by a
holding company controlled by JLL Partners, Inc. (“JLL”) in a
transaction valued at approximately $123 million. Under the terms of the
proposed transaction BioClinica shareholders will receive $7.25 in cash
for each BioClinica share they own.
WeissLaw LLP is investigating whether BioClinica’s Board acted in the
best interests of its public shareholders by actively shopping the
Company to maximize shareholder value for BioClinica’s public
shareholders, prior to entering into the proposed transaction with JLL.
Notably, one analyst set a price target for BioClinica at $9.00 per
share. If you own BioClinica shares and would like more information
about your rights as a shareholder or additional information concerning
our investigation, please contact Michael A. Rogovin either by telephone
at (888) 593-4771 or by email at info@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and derivative
actions for violations of corporate and fiduciary duties. We have
recovered over a billion dollars for defrauded institutions and
individuals and obtained important corporate governance in these cases.
If you have information or would like legal advice concerning possible
corporate wrongdoing (including insider trading, waste of corporate
assets, accounting fraud, or issuing materially misleading information),
consumer fraud (including false advertising, defective products, or
other deceptive business practices), or anti-trust violations, please
email us at info@weisslawllp.com
or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar outcome.
